NEOGENOMICS INC·4

Jun 3, 7:46 PM ET

KANOVSKY STEPHEN M 4

4 · NEOGENOMICS INC · Filed Jun 3, 2026

Research Summary

AI-generated summary of this filing

Updated

NeoGenomics (NEO) Director Stephen Kanovsky Exercises Options, Receives RSUs

What Happened

  • Stephen M. Kanovsky, a director of NeoGenomics Inc. (NEO), exercised/converted a derivative and had restricted stock units (RSUs) released on 2026-06-01. The filing shows acquisition of 23,077 shares via exercise/conversion (exercise price $0.00) and the release/grant-acquisition of 11,069 and 15,970 shares (both derivative/RSU-related). There is also a corresponding reported disposition of 23,077 derivative shares at $0.00. In total the filing records 50,116 shares acquired and 23,077 derivative shares disposed, a net increase of 27,039 shares for the insider per this report. The filing lists $0.00 as the price on these transactions, so no cash payment is shown.

Key Details

  • Transaction date: 2026-06-01 (reported on Form 4 filed 2026-06-03)
  • Recorded transactions:
    • Exercise/conversion (M): 23,077 shares acquired @ $0.00
    • Exercise/conversion (M): 23,077 shares disposed @ $0.00 (derivative)
    • Grant/award release (A): 11,069 shares acquired @ $0.00 (derivative; RSU release)
    • Grant/award release (A): 15,970 shares acquired @ $0.00 (derivative; RSU release)
  • Net change reported on this Form 4: +27,039 shares (50,116 acquired minus 23,077 disposed)
  • Shares owned after the transactions: not stated in the provided filing summary
  • Footnotes in the filing:
    • F1: The reported acquisitions reflect the release of restricted stock units previously reported on a Form 4.
    • F2: Once vested, the released shares of common stock are not subject to expiration.
  • Filing timeliness: Form 4 filed 2 days after the transaction date (appears timely, not marked late)

Context

  • Derivative explanation: The filing shows an exercise/conversion of a derivative instrument and the release of RSUs. When a derivative is exercised or RSUs vest, shares are typically issued to the insider; the $0.00 exercise/price here means the filing shows no cash paid for those reported shares. The separate disposition entry at $0.00 likely reflects an internal conversion/settlement reporting detail rather than an open-market sale for cash.
  • For retail investors: awards and RSU releases are common forms of compensation and do not necessarily signal a buy/sell decision; purchases are generally more informative about insider sentiment. This report documents compensation-related issuance and a net increase in the director’s holdings per the filing.

Insider Transaction Report

Form 4
Period: 2026-06-01
Transactions
  • Exercise/Conversion

    Common Stock

    [F1]
    2026-06-01+23,07775,421 total
  • Exercise/Conversion

    Restricted Stock Unit

    [F2]
    2026-06-0123,0770 total
    Exercise: $0.00From: 2026-06-01Common Stock (23,077 underlying)
  • Award

    Stock Option (Right to Buy)

    2026-06-01+11,06911,069 total
    Exercise: $10.52From: 2027-06-01Exp: 2036-06-01Common Stock (11,069 underlying)
  • Award

    Restricted Stock Unit

    [F2]
    2026-06-01+15,97015,970 total
    Exercise: $0.00From: 2027-06-01Common Stock (15,970 underlying)
Holdings
  • Stock Option (Right to Buy)

    Exercise: $22.52From: 2020-06-06Exp: 2026-06-06Common Stock (4,269 underlying)
    4,269
  • Stock Option (Right to Buy)

    Exercise: $28.54From: 2021-05-28Exp: 2027-05-28Common Stock (3,448 underlying)
    3,448
  • Stock Option (Right to Buy)

    Exercise: $40.90From: 2022-06-02Exp: 2028-06-02Common Stock (3,714 underlying)
    3,714
  • Stock Option (Right to Buy)

    Exercise: $8.10From: 2023-06-10Exp: 2029-06-10Common Stock (13,882 underlying)
    13,882
  • Stock Option (Right to Buy)

    Exercise: $14.82From: 2024-08-10Exp: 2033-08-10Common Stock (8,353 underlying)
    8,353
  • Stock Option (Right to Buy)

    Exercise: $13.71From: 2025-06-01Exp: 2034-06-01Common Stock (8,672 underlying)
    8,672
  • Stock Option (Right to Buy)

    Exercise: $7.28From: 2026-06-01Exp: 2035-06-01Common Stock (16,107 underlying)
    16,107
Footnotes (2)
  • [F1]Reflects the release of restricted stock units that were previously reported on a Form 4.
  • [F2]Once vested, the shares of common stock are not subject to expiration.
Signature
/s/ Ali Olivo, Attorney-in-Fact|2026-06-03

Documents

1 file
  • 4
    wk-form4_1780530371.xmlPrimary

    FORM 4